Chronic Inflammatory Demyelinating Polyneuropathy (cidp) Clinical Trials
2 recruiting trials for Chronic Inflammatory Demyelinating Polyneuropathy (cidp). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Chronic Inflammatory Demyelinating Polyneuropathy (cidp) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Early Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Early Phase 1: 1, Phase 1: 1.
The only sponsor on record for these trials is Tongji Hospital (2 trials).
The most frequently studied intervention is CD19/BCMA-targeted CAR-T cells (biological, 1 trial), followed by Lymphodepleting Conditioning, Universal CD19 CAR-γδT Cell Injection.
Track Chronic Inflammatory Demyelinating Polyneuropathy (cidp) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
This single-arm, open-label investigator-initiated trial (IIT) evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with...
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory...
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy (cidp), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Chronic Inflammatory Demyelinating Polyneuropathy (cidp), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Chronic Inflammatory Demyelinating Polyneuropathy (cidp), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.